Navigation Links
Landmark study analyzes scientific productivity and impact of the top 100 PD investigators
Date:6/9/2011

Amsterdam, NL, June 9, 2011 IOS Press is pleased to announce the publication of a landmark study in which both traditional and innovative scientometric approaches have been employed to identify the top 100 Parkinson's disease (PD) investigators since 1985 and measure their scientific productivity as well as the impact of their contributions to the field. The article appears today in the inaugural issue of the Journal of Parkinson's Disease.

This milestone analysis has been conducted by Aaron A. Sorensen, a noted expert in the fields of scientometrics and bibliometrics and currently Clinical Research Industry Specialist at GE Healthcare, and David Weedon, a Publishing Consultant based in London, formerly Managing Director of Biology Reports Ltd. While the study employs traditional bibliometric techniques to rank investigators, the authors have utilized innovative metrics to complement traditional tools that do not always give a full picture of the impact of a researcher's work.

"The number of citations an article receives is widely accepted as a measure of its impact," commented Sorensen and Weedon. "There has not, however, been a broad analysis of the PD research literature to assess, in a comprehensive manner, the impact and productivity of the top investigators, which this study aims to provide. It is interesting to note that approximately half the names in the Top 20 for the last decade are names that did not appear in the Top 20 for the last 25 years."

The authors have compiled a list of the 100 most cited PD researchers since 1985. The top 20 researchers identified are:

  1. Lees, Andrew J, University College London
  2. Marsden, C David, University College London
  3. Agid, Yves, Piti - Salptrire University Hospital, Paris
  4. Lang, Anthony E, Toronto Western Research Institute
  5. Olanow, C Warren, Mount Sinai School of Medicine, New York, NY
  6. Brooks, David J, Imperial College London
  7. Jenner, Peter, King's College London
  8. Mizuno, Yoshikuni, Juntendo University School of Medicine, Tokyo
  9. Fahn, Stanley, Columbia University, New York, NY
  10. Benabid, Alim-Louis, Joseph Fourier University, Grenoble
  11. Goetz, Christopher G, Rush University Medical Center, Chicago, IL
  12. Quinn, Niall P, University College London
  13. Pollak, Pierre, Joseph Fourier University, Grenoble
  14. Hirsch, Etienne C, Piti - Salptrire University Hospital, Paris
  15. Koller, William C, University of North Carolina, Chapel Hill, NC
  16. Lozano, Andres M, University of Toronto
  17. Riederer, Peter, Universitt Wzburg
  18. Jankovic, Joseph, Baylor College of Medicine, Houston, TX
  19. Daniel, Susan E, University College London
  20. Tanner, Caroline M, The Parkinson's Institute, Sunnyvale, CA

In order to get a sense for how the PD "impact landscape" might have changed in the 21st century, a Top 100 of the last decade was determined. The analysis revealed the names of a considerable number of "rising stars", who have made significant contributions to the PD literature, often through molecular or genetic approaches. The Top 20 identified are:

  1. Lang, Anthony E, Toronto Western Research Institute
  2. Farrer, Matthew, Mayo Clinic, Jacksonville, FL
  3. Lees, Andrew J, University College London
  4. Olanow, C Warren, Mount Sinai School of Medicine, New York, NY
  5. Singleton, Andrew, National Institute of Aging NIH, Bethesda, MD
  6. Przedborski, Serge, Columbia University, New York, NY
  7. Wood, Nicholas W, University College London
  8. Pollak, Pierre, Joseph Fourier University, Grenoble
  9. Benabid, Alim-Louis, Joseph Fourier University, Grenoble
  10. Poewe, Werner, Innsbruck Medical University
  11. Jankovic, Joseph, Baylor College of Medicine, Houston, TX
  12. Fahn, Stanley, Columbia University, New York, NY
  13. Hardy, John, University College London
  14. Agid, Yves, Piti - Salptrire University Hospital, Paris
  15. Lozano, Andres M, University of Toronto
  16. Albanese, Alberto, Universita Cattolica del Sacro Cuore, Milan
  17. Goetz, Christopher G, Rush University Medical Center, Chicago, IL
  18. Dawson, Ted M, Johns Hopkins University, Baltimore, MD
  19. Cookson, Mark R, National Institute on Aging NIH, Bethesda, MD
  20. Maraganore, Demetrius M, Mayo Clinic Minnesota, Rochester, MN

In addition, newer bibliometric methods were used as a means to assess productivity and impact. Researchers were ranked using H-indices (a measure of an author's highly-cited body of work), and "broad impact" citations were introduced as a novel way of identifying those scientists whose PD work has a large "ripple effect" beyond the PD research community.

Parkinson's disease is the second most common neurodegenerative disorder, affecting 1𔃀% of the population over the age of 65. It is characterized by loss of brain cells (neurons) from the mid-brain which use the neurotransmitter dopamine to help control voluntary movements.


'/>"/>

Contact: Daphne Watrin
d.watrin@iospress.nl
31-206-883-355
IOS Press
Source:Eurekalert

Related medicine news :

1. Support for Massachusetts landmark health reform law rises in 2011
2. UT Southwestern pediatricians launch landmark childrens health study
3. Stephen J. Teach, MD, MPH, part of landmark study on pediatric asthma
4. Feeling included -- kids with disabilities have their say in landmark study
5. Landmark report reveals massive global cost of Alzheimers: 1 percent of global GDP -- and growing
6. Landmark Clinical Trial Shows Surgery and Stenting Equally Safe and Effective at Preventing Stroke
7. Endometriosis Foundation of America to Present Landmark Scientific Symposium in NYC
8. China's Forbidden City Leads Landmark Climate Action for Earth Hour
9. Landmark Legal Foundation to File Suit to Stop Presidents Health Plan if Slaughter Rule is Used
10. Foodborne Illness Costs U.S. $152 Billion Annually, Landmark Report Estimates
11. California to Examine Health Impacts of Landmark Cap-and-Trade Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... ... 24, 2017 , ... Accordant Technology, a trusted IT solutions ... an analytics-first approach, layered with machine learning, that provides real-time visibility into the ... cloud to the edge. Through the new partnership, customers get the real-time situational ...
(Date:5/24/2017)... ... May 24, 2017 , ... ... for-profit and nonprofit hospitals and health systems in the nation and help their ... institutions, led professional organizations and been instrumental in developing successful hospital and health ...
(Date:5/23/2017)... City (PRWEB) , ... May 23, 2017 , ... ... Population Health and Clinical Integration company, announced today that its iClinic V12.2 ... Home (PCMH) 2017 Prevalidation. NCQA recently introduced PCMH 2017 standards which emphasize ...
(Date:5/23/2017)... ... May 23, 2017 , ... Cambridge, MA, May 23, 2017—Total ... according to a Workers Compensation Research Institute (WCRI) study, a contrast from the ... System: CompScope™ Benchmarks, 17th Edition looks at indemnity and medical payments for ...
(Date:5/23/2017)... ... May 23, 2017 , ... London, May 23, 2017: ... serve earlier this month as a Guest Speaker and Contributor to a weeklong series ... and Common Purpose. , Walter Schindler and SAIL Capital ...
Breaking Medicine News(10 mins):
(Date:5/15/2017)... 15, 2017 Enterin Inc., a privately-held CNS pharmaceutical ... novel compounds to treat Parkinson,s disease (PD), has enrolled the ... Phase 1/2a randomized, controlled, multicenter study involving patients with PD ... 50 patients over a 9-to-12-month period. The first stage is ... with PD. Participating sites include Denver , ...
(Date:5/10/2017)... 10, 2017  The Corporate Whistleblower Center says, ... sleep therapy clinics to call us anytime at ... is involved in a substantial scheme to overbill ... from an employee of a medical equipment company ... to provide medical practice groups with extra generous incentives ...
(Date:5/9/2017)... May 9, 2017  Oramed Pharmaceuticals Inc. (NASDAQ: ... clinical-stage pharmaceutical company focused on the development of ... Canadian Intellectual Property Office has granted Oramed a ... of Exenatide". The patent covers Oramed,s invention of ... GLP-1 is an incretin hormone that stimulates the ...
Breaking Medicine Technology: